Getinge AB (publ)
Getinge AB (publ) provides products and solutions for operating rooms, intensive-care units, and sterilization departments in Sweden and internationally. The company operates through Acute Care Therapies, Life Science, and Surgical Workflows segments. It provides extracorporeal membrane oxygenation, mechanical ventilation, advanced patient monitoring, ICU infrastructure equipment, and drainage so… Read more
Getinge AB (publ) (GTN0) - Net Assets
Latest net assets as of June 2025: €29.02 Billion EUR
Based on the latest financial reports, Getinge AB (publ) (GTN0) has net assets worth €29.02 Billion EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€56.37 Billion) and total liabilities (€27.35 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €29.02 Billion |
| % of Total Assets | 51.48% |
| Annual Growth Rate | 9.67% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 8.64 |
Getinge AB (publ) - Net Assets Trend (2021–2024)
This chart illustrates how Getinge AB (publ)'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Getinge AB (publ) (2021–2024)
The table below shows the annual net assets of Getinge AB (publ) from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €33.21 Billion | +9.23% |
| 2023-12-31 | €30.40 Billion | -0.16% |
| 2022-12-31 | €30.45 Billion | +20.96% |
| 2021-12-31 | €25.18 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Getinge AB (publ)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 22.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €20.33 Billion | 61.59% |
| Other Components | €12.68 Billion | 38.41% |
| Total Equity | €33.01 Billion | 100.00% |
Getinge AB (publ) Competitors by Market Cap
The table below lists competitors of Getinge AB (publ) ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
BankUnited Inc
NYSE:BKU
|
$3.14 Billion |
|
Geovis Technology Co Ltd
SHG:688568
|
$3.14 Billion |
|
HAKUHODO DY HLDG
MU:HDU
|
$3.14 Billion |
|
JOYY Inc
NASDAQ:JOYY
|
$3.14 Billion |
|
Nexchip Semiconductor Corp. A
SHG:688249
|
$3.14 Billion |
|
Corporate Office Properties Trust
F:WX7
|
$3.14 Billion |
|
JSW Energy Limited
NSE:JSWENERGY
|
$3.13 Billion |
|
VICTORY CAP. CL.A DL-01
F:3PK
|
$3.13 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Getinge AB (publ)'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 30,166,000,000 to 33,005,000,000, a change of 2,839,000,000 (9.4%).
- Net income of 1,638,000,000 contributed positively to equity growth.
- Dividend payments of 1,227,000,000 reduced retained earnings.
- Other factors increased equity by 2,428,000,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €1.64 Billion | +4.96% |
| Dividends Paid | €1.23 Billion | -3.72% |
| Other Changes | €2.43 Billion | +7.36% |
| Total Change | €- | 9.41% |
Book Value vs Market Value Analysis
This analysis compares Getinge AB (publ)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.14x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €90.87 | €17.00 | x |
| 2022-12-31 | €110.28 | €17.00 | x |
| 2023-12-31 | €110.75 | €17.00 | x |
| 2024-12-31 | €121.18 | €17.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Getinge AB (publ) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.96%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4.71%
- • Asset Turnover: 0.54x
- • Equity Multiplier: 1.94x
- Recent ROE (4.96%) is below the historical average (8.31%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 12.00% | 10.98% | 0.61x | 1.80x | €495.10 Million |
| 2022 | 8.29% | 8.80% | 0.54x | 1.73x | €-512.80 Million |
| 2023 | 8.00% | 7.58% | 0.59x | 1.78x | €-604.60 Million |
| 2024 | 4.96% | 4.71% | 0.54x | 1.94x | €-1.66 Billion |
Industry Comparison
This section compares Getinge AB (publ)'s net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $253,026,393
- Average return on equity (ROE) among peers: -74.55%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Getinge AB (publ) (GTN0) | €29.02 Billion | 12.00% | 0.94x | $3.14 Billion |
| HeraMED Limited (1I4) | $-105.98K | 0.00% | 0.00x | $18.56 Million |
| Q-linea AB (publ) (3F80) | $163.19 Million | -164.65% | 0.41x | $9.44 Million |
| Guerbet SA (4G8) | $342.14 Million | 13.51% | 1.79x | $44.18 Million |
| Scandinavian Real Heart AB (Publ) (7820) | $111.29 Million | -9.42% | 0.06x | $4.94 Million |
| aap Implantate AG (AAQ1) | $54.78 Million | 26.71% | 0.17x | $9.65 Million |
| Carmat SA (CXT) | $7.48 Million | -557.76% | 3.92x | $1.62 Million |
| elexxion AG (E8X) | $-0.01 | 0.00% | 0.00x | $199.10K |
| AETHLON MEDIC.NEW DL-001 (EJU) | $15.06 Million | -79.86% | 0.16x | $446.12K |
| Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ) | $139.44 Million | 15.79% | 0.97x | $615.93 Million |
| Gaush Meditech Ltd (F7Y) | $1.70 Billion | 10.23% | 0.68x | $29.29 Million |